

FOR IMMEDIATE RELEASE

Syntermed Acquires Emory Cardiac Toolbox, Rebrands as *Cardiac Toolbox (eCTB)*

Atlanta, GA — September 4, 2025 — Syntermed Inc, the exclusive licensee of the Emory Cardiac Toolbox for more than 25 years, today announced it has acquired the rights to the software suite and will rebrand the product as **Cardiac Toolbox™ (eCTB™)**. The acquisition marks a significant milestone in Syntermed's long-standing collaboration with Emory University and positions the company to expand innovation in cardiac imaging worldwide.

"This acquisition was a natural next step in the evolution of our relationship with Emory University," said Michael Lee, CEO of Syntermed. "Rebranding as *Cardiac Toolbox (eCTB)* reflects both the strength of its history and the exciting future ahead. This acquisition will allow us to accelerate product development and innovation, particularly with the continued scientific leadership of Dr. Ernie Garcia, Syntermed's Chief Scientific Advisor for Cardiology."

Dr. Garcia, who served as the principal investigator for the Emory Cardiac Toolbox during his distinguished tenure at Emory University, recently retired from his academic role. He will continue to serve as Chief Scientific Advisor for Cardiology at Syntermed. In his role, Dr. Garcia will provide scientific direction to guide new product features, ensure clinical excellence, and extend the legacy of innovation that has made the Toolbox one of the most trusted solutions in nuclear cardiology.

The newly branded *Cardiac Toolbox (eCTB)* will maintain its reputation as a comprehensive and reliable platform for cardiac imaging analysis. For decades, the Toolbox has supported cardiologists and nuclear medicine specialists with advanced tools for diagnosing and managing patients with cardiovascular disease. With Syntermed's full ownership, the company will accelerate investment in research and development, expand functionality, and deliver next-generation capabilities to meet the evolving needs of physicians and patients.

About Syntermed, Inc.

Syntermed, Inc., an Atlanta-based imaging and informatics software company, is a global leader in providing Cardiac, NeuroRadiology, and Oncology imaging software solutions. Committed to innovation and excellence, Syntermed develops products that help clinicians diagnose and manage complex medical conditions with confidence and precision. Signature products include Cardiac Toolbox™, NeuroQ™, and Syntermed Live™. Cardiac Toolbox™

Nuclear is evolving. We're evolving with you.

incorporates an FDA 510 K-cleared Intelligent Decision Support (IDS) platform for quantifying and reporting MPI SPECT/PET studies. NeuroQ™ is one of the most widely utilized software solutions for quantifying brain PET-FDG, Amyloid, SPECT, DaTscan, and Epilepsy studies. Syntermed Live™, which currently hosts almost 1M studies, is a cloud-based and HIPAA-compliant platform used by nuclear medicine physicians to get round-the-clock secure, remote access to their studies and reports no matter where they are. All Syntermed solutions are 510K cleared, MDD cleared (MDR in process), ISO Certified, carry the CE Mark and are compatible with virtually any nuclear medicine workstation or PC/MAC that supports the Microsoft® Windows® operating system. Syntermed products and services are available worldwide from leading OEMs, Value-Add Resellers, and Solution Providers.

For more information, contact digitalmedia@syntermed.com or call 888-263-4446 ext. 3